Navigation Links
Moderna Therapeutics Named a "Fierce 15" Biotech Company for 2013
Date:9/24/2013

CAMBRIDGE, Mass., Sept. 24, 2013 /PRNewswire/ -- Moderna Therapeutics, the pioneering company developing messenger RNA therapeutics™, a revolutionary new treatment modality to enable the in vivo production of therapeutic proteins, announced today that FierceBiotech has named Moderna as one of 2013's Fierce 15.

The award designates Moderna as one of the most promising private companies in the biotech industry. Companies from around the world are selected based on strength of technology, venture funding, and their potential to positively impact the treatment of human diseases.

"With its messenger RNA therapies, Moderna has the potential to reinvent the way protein therapies are developed and created," says Executive Editor Ryan McBride. "AstraZeneca validated this potential in a landmark deal that gives Moderna the cash and resources to become a major player in oncology and rare diseases, making this company one to watch closely."

"We are honored to be selected as a Fierce 15 company and recognized for our vision in the field of messenger RNA therapeutics™," said Stephane Bancel, president and founding CEO of Moderna. "This award comes at an exciting time for us, as we recently published our first proof of concept study in Nature Biotechnology, providing important validation of our platform's potential to treat many diseases that cannot be addressed today. We are thrilled to be moving forward quickly and safely to translate our technology into treatment for patients in need."

About Moderna Therapeutics

Moderna is pioneering messenger RNA therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. This breakthrough platform addresses currently undruggable targets and offers a superior alterna
'/>"/>

SOURCE Moderna Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Henri A. Termeer Joins Moderna Therapeutics Board Of Directors
2. Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer
3. Biotech Industry Veteran Joseph Bolen Joins Moderna Therapeutics to be President of Research and Development
4. Study Published in Nature Biotechnology Demonstrates Ability of Modernas Novel Therapeutic Paradigm to Repair and Regenerate Damaged Heart Tissue
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
8. Fate Therapeutics Strengthens Its iPSC Platform
9. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
10. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
11. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Nanoparticles, engineered materials about a billionth of a meter ... are tiny, they can benefit human health, as in ... interfere with it through viruses, air pollution, traffic emissions, ... at Washington University in St. Louis, led by Lan ... in Electrical & Systems Engineering, and their collaborators at ...
(Date:9/2/2014)... 2014 Press attending the Project LIBERTY ... advantage of the people and events in Emmetsburg on ... available throughout the day. Additionally, we will do our ... DSM representatives as well as representatives from the local ... , Please remember to RSVP to Matt Merritt ...
(Date:9/2/2014)... , Sept. 2, 2014  Technology Applications International ... that its wholly-owned subsidiary Renuell Int,l, Inc. has signed ... and Space Administration ("NASA") at the Johnson Space Center ... See photos: tapplic.com/houstonphotos/ ... are very pleased to announce our latest, exclusive agreement ...
(Date:9/2/2014)... 2014 Orexigen Therapeutics, Inc. (Nasdaq: ... Trademark Office (PTO) has issued a patent related to ... loss. NB32 is a fixed-dose combination of naltrexone sustained ... No. 8,815,889 claims methods for treating insulin resistance using ... in 2024. If NB32 is approved for use in ...
Breaking Biology Technology:Engineers develop new sensor to detect tiny individual nanoparticles 2Engineers develop new sensor to detect tiny individual nanoparticles 3Press agenda for Project LIBERTY Grand Opening 2Press agenda for Project LIBERTY Grand Opening 3Press agenda for Project LIBERTY Grand Opening 4Press agenda for Project LIBERTY Grand Opening 5Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 2Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 4
... (Nasdaq: NTII ), today announced that Paul E. ... Rodman & Renshaw,10th Annual Healthcare Conference November 10 to ... presentation will take place at 3:15 p.m. (ET) on,November ... be accessed by going to:, http://investor.shareholder.com/ntii/events.cfm , ...
... of $0.73, up 192% from third quarter 2007, - New business ... business authorizations of $1 billion at Sept. 30, 2008, up 16% ... from Dec. ... global full-service clinical research organization, today reported,record net income of $11.0 million or ...
... 67% from Same Prior Year Period, DUBLIN, Calif., ... pharmaceutical company dedicated to the discovery and,development of novel ... and nine months ended September 30, 2008., Total ... compared,with $6.1 million for the same prior year period. ...
Cached Biology Technology:Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations 2Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations 3Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations 4Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations 5Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations 6Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations 7Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations 8SuperGen Reports 2008 Third Quarter Financial Results 2SuperGen Reports 2008 Third Quarter Financial Results 3SuperGen Reports 2008 Third Quarter Financial Results 4SuperGen Reports 2008 Third Quarter Financial Results 5SuperGen Reports 2008 Third Quarter Financial Results 6SuperGen Reports 2008 Third Quarter Financial Results 7SuperGen Reports 2008 Third Quarter Financial Results 8SuperGen Reports 2008 Third Quarter Financial Results 9SuperGen Reports 2008 Third Quarter Financial Results 10
(Date:9/2/2014)... Air pollution regulations over the last decade in Taiyuan, ... there, accounting for a greater than 50% reduction in ... 2001 and 2010, according to researchers at the Columbia ... School of Public Health, the Shanxi Medical University, the ... and Shanghai Fudan University School of Public Health. , ...
(Date:9/2/2014)... In Bavaria, the Tithonian Konservat-Lagersttte of lithographic limestone ... discoveries of emblematic fossils from that area (for ... have found fossil insects in the French equivalent ... new species representing the oldest known water treader. ... equivalent Bavarian outcrops, fewer fossils have been obtained ...
(Date:9/2/2014)... stress in stride; others are done in by it. ... mechanisms of this so-called stress gap in mice with ... lead researchers to better understand the development of psychiatric ... each animal has unique experiences as it goes through ... can alter the expression of genes, and as a ...
Breaking Biology News(10 mins):Clean air halves health costs in Chinese city 2Exceptionally well preserved insect fossils from the Rhône Valley 2Discovery hints at why stress is more devastating for some 2Discovery hints at why stress is more devastating for some 3
... of the human genetic code to determine why some people,s blood ... Johns Hopkins and in Boston have found a septet of overactive ... results give us a clear set of new molecular targets, the ... us identify people more at risk for blood clots and for ...
... A protein whose primary role is in the ... role in treating kidney failure. Indiana University ... kidney injury in laboratory experiments using cells that ... research suggests there could be a potential future ...
... In August of 2008 Jacob Schaefer, PhD, on vacation in San ... As it happened, the newspaper was running a series on the ... are more frequent they now occur every few years instead ... The more intense fire cycle is fueled by cheatgrass (Bromus ...
Cached Biology News:Genetic septet in control of blood platelet clotting 2Genetic septet in control of blood platelet clotting 3Genetically modified cell procedure may prove useful in treating kidney failure 2In elevated carbon dioxide, soybeans stumble but cheatgrass keeps on truckin' 2In elevated carbon dioxide, soybeans stumble but cheatgrass keeps on truckin' 3In elevated carbon dioxide, soybeans stumble but cheatgrass keeps on truckin' 4In elevated carbon dioxide, soybeans stumble but cheatgrass keeps on truckin' 5
... EZ DNA Methylation Kit uses a simplified ... DNA methylation analysis. The kit is based ... place between cytosine and sodium bisulfite where ... DNA Methylation Kits innovative in-column desulphonation reaction ...
... EnzoLyte MG Phosphate Assay Kit is ... formed between Malachite Green, molybdate and free ... reaction can be conveniently measured on a ... reader. The non-radioactive colorimetric assay kits have ...
... of digital x-ray detectors from KUBTEC represents ... with 12 to 16 bit digital interface. ... photodiode array sensor with pixel spacing down ... in low x-ray energies (10-50 kV) and ...
... Arrays are intended for laboratory research use ... in neutral buffered formalin and embedded in ... performed by certified pathologists. Tissue cores ... relocated into a new recipient paraffin block, ...
Biology Products: